efp*****a



Conflicts of interest – industry view

Richard Bergstrom

EFPIA Director-General

Principles

- * Important to separate personal from institutional relations
- * "Expert witness" is a great concept (cf US FDA)
- * Some relations are no "conflicts", such as clinical research
- * Medicines development is a public-partnership; different from most sectors
- * Important with visible whistle-blower function
- * Industry will contribute by introducing "sunshine" provisions from 2015/2016: disclosure of payments (ToV: transfers of value) to health care professionals (HCPs) and health care organisations (HCOs)



First Disclosures in 2016

Level of Disclosure	2016 based on 2015 data
<u>Aggregate</u>	Research & Development ToV to HCPs/HCOs related to the planning and conduct of: a. Non-clinical studies (as defined in the OECD Principles of GLP) b. Clinical trials (as defined in Directive 2001/20/EC) c. Non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study (cfr Section 15.02 of the EFPIA HCP Code)
Individual HCO "following the money"	Donations & Grants to HCOs Contribution to costs of events ➤ Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an event ➤ Registration fees ➤ Travel & accommodation Fee-for-service & consultancy ➤ Fees ➤ Related expenses agreed in the fees for service or consultancy contract
Individual HCP "following the money"	Contribution to costs of events ➤ Registration fees ➤ Travel & accommodation Fees for service & consultancy ➤ Fees ➤ Related expenses agreed in the fees for service or consultancy contract

Each company shall publish a note summarising the methodologies used in preparing their disclosures and identifying transfers of value for each category described above.

efp*ta



EFPIA Brussels Office

Leopold Plaza Building Rue du Trône 108 B-1050 Brussels - Belgium Tel: +32 (0)2 626 25 55

www.efpia.eu